TY - JOUR T1 - Mechanistic-statistical SIR modelling for early estimation of the actual number of cases and mortality rate from COVID-19 JF - medRxiv DO - 10.1101/2020.03.22.20040915 SP - 2020.03.22.20040915 AU - Lionel Roques AU - Etienne Klein AU - Julien Papaïx AU - Samuel Soubeyrand Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/03/24/2020.03.22.20040915.abstract N2 - The first cases of COVID-19 in France were detected on January 24, 2020. The number of screening tests carried out and the methodology used to target the patients tested do not allow for a direct computation of the actual number of cases and the mortality rate. In this note, we develop a ‘mechanistic-statistical’ approach coupling a SIR ODE model describing the unobserved epidemiological dynamics, a probabilistic model describing the data acquisition process and a statistical inference method. The objective of this model is not to make forecasts but to estimate the actual number of people infected with COVID-19 during the observation window in France and to deduce the mortality rate associated with the epidemic.Main results The actual number of infected cases in France is probably much higher than the observations: we find here a factor ×15 (95%-CI: 4 − 33), which leads to a 5.2/1000 mortality rate (95%-CI: 1.5/1000 − 11.7/1000) at the end of the observation period. We find a R0 of 4.8, a high value which may be linked to the long viral shedding period of 20 days.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by INRAEAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll of the data in this manuscript are available from public sources: Johns Hopkins University Center for Systems Science and Engineering, Santé publique France, and Korean Center for Disease Control https://github.com/CSSEGISandData/COVID-19 ER -